1. Comprehensive analysis of Epha10 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in non-small cell lung cancer.
- Author
-
Wang A, Zhu J, Li Y, Jiao M, Zhang S, Ding ZL, Huang JA, and Liu Z
- Subjects
- Humans, Prognosis, Immune Checkpoint Inhibitors therapeutic use, Gene Expression Regulation, Neoplastic, Receptors, Eph Family metabolism, Receptors, Eph Family genetics, Female, Male, Gene Expression Profiling, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms genetics, Lung Neoplasms drug therapy, Lung Neoplasms mortality, Lung Neoplasms metabolism, Lung Neoplasms pathology, Biomarkers, Tumor metabolism, Biomarkers, Tumor genetics
- Abstract
The EphA family belongs to a large group of membrane receptor tyrosine kinases. Emerging evidence indicates that the EphA family participates in tumour occurrence and progression. Nonetheless, the expression patterns and prognostic values of the nine EphAs in non-small cell lung cancer (NSCLC) have rarely been studied before. In the current study, we comprehensively analysed the expression and prognostic role of EphA family members by different means. The Cancer Genome Atlas and Gene Expression Profiling Interactive Analysis databases were used to investigate the expression of EphAs in NSCLC. The cBioPortal database was applied to analyse the prognostic values and genetic mutations of EphAs.We discovered that the expression of EphA10 was significantly higher in NSCLC tissues than in adjacent noncancerous tissues, and survival analyses showed that a higher level of EphA10 predicted poor prognosis. Further exploration into the role of EphA10 by ESTIMATE, CIBERSORT, and ssGSEA analysis found that it was also related to immune infiltration and higher expression of targets of ICI targets. In conclusion, this study revealed that among the EphA family members, EphA10 played an oncogenic role and was a promising biomarker for poor prognosis and better immunotherapy response in NSCLC., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF